Everest Medicines (HKSE:01952) Debt-to-Equity : 0.14 (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines Debt-to-Equity?

Everest Medicines's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was HK$493.9 Mil. Everest Medicines's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was HK$92.5 Mil. Everest Medicines's Total Stockholders Equity for the quarter that ended in Dec. 2024 was HK$4,348.4 Mil. Everest Medicines's debt to equity for the quarter that ended in Dec. 2024 was 0.13.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Everest Medicines's Debt-to-Equity or its related term are showing as below:

HKSE:01952' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.37 Med: 0.07 Max: 0.14
Current: 0.14

During the past 7 years, the highest Debt-to-Equity Ratio of Everest Medicines was 0.14. The lowest was -0.37. And the median was 0.07.

HKSE:01952's Debt-to-Equity is ranked better than
50.74% of 1013 companies
in the Biotechnology industry
Industry Median: 0.14 vs HKSE:01952: 0.14

Everest Medicines Debt-to-Equity Historical Data

The historical data trend for Everest Medicines's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines Debt-to-Equity Chart

Everest Medicines Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

0.07

0.08

0.01

0.10

0.14

Everest Medicines Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial							0.01	0.05	0.10	0.12	0.14

Competitive Comparison of Everest Medicines's Debt-to-Equity

For the Biotechnology subindustry, Everest Medicines's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Everest Medicines's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Everest Medicines's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Everest Medicines's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Everest Medicines Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Everest Medicines's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(493.932	+	92.479)	/	4348.408
	=	0.13

Everest Medicines's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(493.932	+	92.479)	/	4348.408
	=	0.13

Everest Medicines (HKSE:01952) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Everest Medicines Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Everest Medicines's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Everest Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

6HN:Germany

Address

1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041

Website

https://www.everestmedicines.com

Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.

Executives

Fu Wei	2307 Founder of a discretionary trust who can infl
Nova Aqua Limited	2201 Interest of corporation controlled by you
C-bridge Capital Gp Iv, Ltd.	2201 Interest of corporation controlled by you
C-bridge Healthcare Fund Gp Iv, L.p.	2201 Interest of corporation controlled by you
C-bridge Healthcare Fund Iv, L.p.	2201 Interest of corporation controlled by you
Tf Capital Iv Ltd.	2201 Interest of corporation controlled by you
C-bridge Capital Gp, Ltd.	2501 Other
C-bridge Healthcare Fund Gp Ii, L.p.	2501 Other
C-bridge Healthcare Fund Ii, L.p.	2501 Other
C-bridge Investment Everest Limited	2501 Other
Tf Capital Ii Ltd.	2501 Other
Everest Management Holding Co., Ltd.	2101 Beneficial owner
Fu Wei	2307 Founder of a discretionary trust who can infl
C-bridge Joint Value Creation Limited	2201 Interest of corporation controlled by you
Kolchinsky Anna Inge Leonore Haas	2202 Interest of your spouse

Everest Medicines Headlines

No Headlines